Loading...
XASE
NBY
Market cap7mUSD
Dec 05, Last price  
1.21USD
1D
11.01%
1Q
-67.56%
Jan 2017
-99.97%
IPO
-100.00%
Name

NovaBay Pharmaceuticals Inc

Chart & Performance

D1W1MN
XASE:NBY chart
P/E
—
P/S
0.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
40.59%
Rev. gr., 5y
8.19%
Revenues
10m
-33.58%
01,533,0005,913,0006,722,00015,684,0009,754,00011,019,0006,947,0003,477,0001,054,0004,381,00011,897,00018,230,00012,508,0006,599,0009,934,0008,421,00014,404,00014,726,0009,781,000
Net income
-7m
L-25.07%
-3,463,000-5,286,000-5,400,000-8,114,0002,697,000-4,308,000-5,085,000-7,027,000-16,042,000-15,194,000-18,973,000-13,151,000-7,403,000-6,545,000-10,487,000-11,039,000-6,559,000-16,265,000-9,640,000-7,223,000
CFO
-5m
L+25.47%
-3,230,0004,744,000-6,271,000-9,942,000-1,648,0002,028,000-3,142,000-6,528,000-12,969,000-15,055,000-18,559,000-12,135,000-6,270,000-5,568,000-7,929,000-4,721,000-9,192,000-6,654,000-4,131,000-5,183,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
URL
https://novabay.com/
IPO date
Oct 26, 2007
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT